Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors

share with twitter share with LinkedIn share with facebook
09/17/2020 | 04:15am EDT
SPECIALIZED PRESS
Thursday - September 17, 2020
Bitte JavaScript aktivieren / Please enable JavaScript



About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Find more information at www.pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Disclaimer

Bayer AG published this content on 17 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2020 07:14:09 UTC


share with twitter share with LinkedIn share with facebook
All news about BAYER AG
09:47aBAYER : Rivaroxaban application submitted to U.S. FDA for new indication in pati..
AQ
09:46aBAYER : acquires Asklepios BioPharmaceutical to broaden innovation base in cell ..
AQ
09:32aBAYER : Appoints New Head of R&D at Pharmaceuticals
DJ
09:10aBAYER : appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research an..
PU
05:51aCapgemini shares advance on better-than-expected Q3 growth
RE
10/26Health Care Shares Decline as Covid-19 Continues to Dominate Headlines -- Hea..
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26WALL STREET STOCK EXCHANGE : US companies under China sanctions, Many acquisitio..
More news
Financials
Sales 2020 42 947 M 50 791 M 50 791 M
Net income 2020 -4 852 M -5 738 M -5 738 M
Net Debt 2020 32 409 M 38 329 M 38 329 M
P/E ratio 2020 -7,02x
Yield 2020 5,68%
Capitalization 41 807 M 49 406 M 49 443 M
EV / Sales 2020 1,73x
EV / Sales 2021 1,69x
Nbr of Employees 101 168
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 67,53 €
Last Close Price 42,56 €
Spread / Highest target 116%
Spread / Average Target 58,7%
Spread / Lowest Target 8,10%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-41.55%49 406
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381